Seminars in Oncology
Volume 36, Issue 2 , Pages 106-111 , April 2009

Surgical Management of Recurrent Ovarian Cancer

  • Mario M. Leitao Jr

      Affiliations

    • Corresponding Author InformationAddress correspondence to Mario M. Leitao Jr, MD, Memorial Sloan-Kettering Cancer Center, Gynecology Service, Department of Surgery, 1275 York Ave, New York, NY 10065
    • ,
  • Dennis S. Chi

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  3. Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer. 1993;71:1534–1540
  4. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol. 2006;103:559–564
  5. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–1259
  6. Tingulstad S, Skjeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol. 2003;102:499–505
  7. Aletti GD, Gostout BS, Podratz KC, Cliby WA. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol. 2006;100:33–37
  8. Earle CC, Schrag D, Neville BA, Yabroff KR, Tobor M, Fahey A. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006;98:172–180
  9. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:43
  10. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist. 2001;6(Suppl 3):30–35
  11. Goldie JH, Coldman JA. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;3:1727–1733
  12. Bristow RE, Puri I, Chi DS. Secondary cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2008;108:S119
  13. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gyneol. 1983;61:189–193
  14. Segna R, Dottino PR, Mandeli JPP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol. 1993;11:434–439
  15. Lichtenegger W, Sehouli J, Buchmann E, Karajanev C, Weidemann H. Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC). J Obstet Gynaecol Res. 1998;24:447–451
  16. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88:144–153
  17. Zang RY, Zhang ZY, Li ZT, Chen J, Tang MQ, Liu Q, et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol. 2000;75:24–30
  18. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001;83:504–512
  19. Zang Ry, Li ZT, Zhang ZY, Cai S-M. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study. Int J Gynecol Cancer. 2003;13:419–427
  20. Zang Ry, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?. Cancer. 2004;100:1152–1161
  21. Ayhan A, Gultekin M, Taskiran C, Aksan G, Celik NY, Dursun P, et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol. 2006;194:49–56
  22. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933–1939
  23. Harter P, du Bois A, Hahmann M, Burges A, Loibl S, Gropp M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702–1710
  24. Salani R, Santillan A, Zahurak ML, Giuntoli RL, Gardner GJ, Armstrong DK. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109:685–691
  25. Tebes SJ, Sayer RA, Palmer JM, Tebes CC, Martino MA, Hoffman MS. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2007;106:482–487
  26. Leitao MM, Kardos S, Barakat RR, Chi DS. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol. 2004;95:181–188
  27. Karam AK, Santillan A, Bristow RE, Giantoli R, Gardner GJ, Cass I, et al. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol Oncol. 2007;104:377–380
  28. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble E, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89:1532–1540
  29. Funt SA, Hricak H, Abu-Rustum N, Mazumdar M, Felderman H, Chi DS. Role of CT in the management of recurrent ovarian cancer. AJR Am J Roentgenol. 2004;182:393–398
  30. Sugarbaker PH. Surgical oncology: contemporary principles and practice. In:  Bland Ki,  Daly JM,  Karakousis CP editor. Management of peritoneal surface malignancy: appendix cancer and pseudomyxoma peritonei, colon cancer, gastric cancer, abdominopelvic sarcoma, and primary peritoneal malignancy. New York, NY: McGraw-Hill; 2001;p. 1149–1176
  31. Helm CW, Randall-Whitis L, Martin RS, Metzinger DS, Gordinier ME, Parker LP, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol. 2007;105:90–96
  32. Cotte E, Glehen O, Mohammed F, Larny F, Falandry C, Golfier F, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg. 2007;31:1813–1820
  33. Meyn RE, Corry PM, Fletcher SE, Demetriades M. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminechloroplatinum(II). Cancer Res. 1980;40:1136–1139
  34. Alberts DS, Peng YM, Chen HS, Moon TE, Cetas TC, Hoeschele JD. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Cancer Inst. 1980;65:455–461
  35. Feuer DJ, Broadley KE, Shepherd JH, Barton DP. Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. Gynecol Oncol. 1999;75:313–322
  36. van Ooijen B, van der Burg MEL, Planting AST, Siersema SD, Wiggers T. Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin. Surg Gynecol Obstet. 1993;176:469–474
  37. Ripamonti C, Bruera E. Palliative management of malignant bowel obstruction. Int J Gynecol Cancer. 2002;12:135–143
  38. Winter WE, McBroom JW, Carlson JW, Rose GS, Elkas JC. The utility of gastrojejunostomy in secondary cytoreduction and palliation of proximal intestinal obstruction in recurrent ovarian cancer. Gynecol Oncol. 2003;91:261–264
  39. Pothuri B, Vaidya A, Aghajanian C, Venkatraman E, Barakat RR, Chi DS. Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol. 2003;89:306–313
  40. Mangili G, Aletti G, Frigerio L, Franchi M, Panacci N, Vigano R, et al. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer. 2005;15:830–835
  41. von Gruenigen VE, Frasure HE, Reidy AM, Gil KM. Clinical disease course during the last year in ovarian cancer. Gynecol Oncol. 2003;90:619–624
  42. Pothuri B, Montemarano M, Gerardi M, Shike M, Ben-Porat L, Sabbatini P, et al. Percutaneous endoscopic gastrotomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol. 2005;96:330–334
  43. Brard L, Weitzen S, Strubel-Lagan SL, Swamy N, Gorinier ME, Moore RG, et al. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol Oncol. 2006;103:176–180

PII: S0093-7754(08)00259-5

doi: 10.1053/j.seminoncol.2008.12.002

Seminars in Oncology
Volume 36, Issue 2 , Pages 106-111 , April 2009

Article Tools

* Image Usage & Resolution